ABSTRACT
Background Large population-based DNA biobanks linked to electronic health records (EHRs) may provide novel opportunities to identify genetic drivers of ARDS.
Research Question Can we develop an EHR-based algorithm to identify ARDS in a biobank database, and can this validate a previously reported ARDS genetic risk factor?
Study Design and Methods We analyzed two parallel genotyped cohorts: a prospective biomarker cohort of critically ill adults (VALID), and a retrospective cohort of hospitalized participants enrolled in a de-identified EHR biobank (BioVU). ARDS was identified by clinician-investigator review in VALID and an EHR algorithm in BioVU (EHR-ARDS). We tested the association between the MUC5B promoter polymorphism rs35705950 with development of ARDS, and assessed if age modified this genetic association in each cohort.
Results In VALID, 2,795 patients were included, age was 55 [43, 66] (median [IQR]) years, and 718 (25.7%) developed ARDS. In BioVU, 9,025 hospitalized participants were included, age was 60 [48, 70] years, and 1,056 (11.7%) developed EHR-ARDS. We observed a significant age-related interaction effect on ARDS in VALID: among older patients, rs35705950 was associated with increased ARDS risk (OR: 1.44; 95%CI 1.08-1.92; p=0.012) whereas among younger patients this effect was absent (OR: 0.84; 95%CI: 0.62-1.14; p=0.26). In BioVU, rs35705950 was associated with increased risk for EHR-ARDS among all participants (OR: 1.20; 95%CI: 1.00-1.43, p=0.043) and this did not vary by age. The polymorphism was also associated worse oxygenation in mechanically ventilated BioVU participants, but had no association with oxygenation in VALID.
Interpretation The MUC5B promoter polymorphism was associated with ARDS in two cohorts of at-risk adults. Although age-related effect modification was observed only in VALID, BioVU identified a consistent association between MUC5B and ARDS risk regardless of age, and a novel association with oxygenation impairment. Our study highlights the potential for EHR biobanks to enable precision-medicine ARDS studies.
Competing Interest Statement
Dr. Ware reports consulting fees from Novartis, Arrowhead, Akebia, and Global Blood Therapeutics, stock ownership in Virtuoso Surgical, and institutional research contracts with Genentech, Inc. and Bluejay Diagnostics The remaining authors report no conflicts of interest with the reported study.
Funding Statement
Research reported in this publication was supported by the National Institutes of Health under award numbers: NIH K01HL157755 (VEK); NIH R01HL158906 and R01HL164937 (LBW), NIH R01 HL126671 (JAB); NIH R35 HL150783 (JAB); NIH R01 HL171809 and R56 AG084550 (QF and WQW); and research contract funds from Genentech Inc. The project publication described was also supported by CTSA award No. UL1TR002243 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. This research was also supported by Courtneys Race for the Acute Respiratory Distress Syndrome Cure and the Courtney Charneco Family.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of Vanderbilt University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Institution: All work was performed at Vanderbilt University Medical Center, Nashville, Tennessee.
Conflicts of Interest: Dr. Ware reports consulting fees from Novartis, Arrowhead, Akebia, and Global Blood Therapeutics, stock ownership in Virtuoso Surgical, and institutional research contracts with Genentech, Inc. and Bluejay Diagnostics The remaining authors report no conflicts of interest with the reported study.
Financial Support: Research reported in this publication was supported by the National Institutes of Health under award numbers: NIH K01HL157755 (VEK), NIH R01HL158906 and R01HL164937 (LBW), NIH R01 HL126671 (JAB), NIH R35 HL150783 (JAB), NIH R01 HL171809 and R56 AG084550 (QF and WQW) and research contract funds from Genentech, Inc. The project publication described was also supported by CTSA award No. UL1TR002243 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. This research was also supported by Courtney’s Race for the Acute Respiratory Distress Syndrome Cure and the Courtney Charneco Family.
Prior Presentation: Portions of this study were previously presented at the American Thoracic Society 2022 International Conference (May 17, 2022, San Francisco, California) and the Sixth International ARDS Conference (June 19, 2023, Dublin, Ireland).
1. Updated Funding Sources in title page to reflect funding sources of co-authors WQW and QF. 2. Updated Abstract and Main text for word count and clarity. 3. Updated Abstract to indicated that an additional purpose of the study was to develop an EHR-ARDS classifier for our institutional biobank, and that no association was observed between rs35705950 and oxygenation impairment in VALID cohort. 4. Updated Introduction to clarify that some VALID patients included in this study were also included in the previously reported study. 5. Updated Methods section to clarify enrollment period for BioVU participants. 6. Updated Table 1 to include information on admitting ICUs and ICU length of stay for both VALID and BioVU cohorts. Updated information on Berlin ARDS severity to limit only to patients/participants with ARDS/EHR-ARDS. 7. Updated Table 2 to also include estimates and 95% confidence intervals of classifier performance metrics in each cohort. Also added data on F1 scores. 8. Updated Figure 3 to include additional subgroup analysis of BioVU participants admitted to an ICU. Removed extraneous background information on institutional development of the BioVU cohort, instead provided reference to previous published manuscripts on this subject. 9. Added additional references to Cohen's Kappa and review of machine learning algorithms for detection of ARDS.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
ABBREVIATIONS
- ARDS
- (Acute Respiratory Distress Syndrome)
- EHR
- (Electronic Health Record)
- MUC5B
- (Mucin 5B)
- NPV
- (negative predictive value)
- PPV
- (positive predictive value)
- ILD
- (Interstitial lung disease)
- VALID
- (Validating Acute Lung Injury biomarkers for Diagnosis)
